CTLA4 and metastatic melanoma: We could not identify any datasets including anti-PD-1/PD-L1 therapy, but in a cohort of 110 patients with metastatic melanoma with survival data post anti-CTLA-4 ipilimumab, transcriptional profiles were available in 40.